Anacor Pharma (ANAC) Misses Q1 EPS by 1c

Anacor Pharma (NASDAQ: ANAC) reported Q1 EPS of ($0.36), $0.01 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $17.54 million versus the consensus estimate of $19.53 million.

Cash, cash equivalents and investments totaled $137.9 million as of March 31, 2016, compared to $144.4 million as of December 31, 2015. Balances as of March 31, 2016 and December 31, 2015 included cash and cash equivalents of $25.0 million and $53.7 million, short-term investments of $110.6 million and $87.9 million and restricted investments of $2.2 million and $2.8 million, respectively.

“This is an exciting time for Anacor. In January 2016, we submitted our NDA for crisaborole topical ointment, 2%, to the FDA ahead of schedule. The FDA has accepted the crisaborole NDA for review with a PDUFA goal date of January 7, 2017. We believe there is a significant unmet medical need for a novel non-steroidal topical anti-inflammatory treatment option for patients suffering with mild-to-moderate atopic dermatitis, and we look forward to working with the FDA during the regulatory review process,” said Paul L. Berns, Anacor’s Chairman and Chief Executive Officer. “We believe that we are well positioned to execute our commercial strategy in support of the launch of crisaborole, if approved, in the U.S.”

For earnings history and earnings-related data on Anacor Pharma (ANAC) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Palo Alto Networks (PANW) PT Raised to $400 at TD Cowen
• S&P 500 eyes record as retail slump, Iran risk set up pivotal week